Geron (GERN) +7.4% premarket after agreeing to sell its shuttered embryonic stem cell assets to...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) +7.4% premarket after agreeing to sell its shuttered embryonic stem cell assets to BioTime (BTX), according to a non-binding letter of intent. The deal comes a year after GERN shut down the world's first trial of embryonic stem cells in humans. BTX says it arranged for a $10M investment from an undisclosed private investor to finance the proposed deal.